Coeptis Therapeutics Holdings, Inc.
COEP
$15.92
-$0.04-0.25%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 55.36% | 20.18% | -12.55% | -52.23% | -52.22% |
| Depreciation & Amortization | 0.00% | 0.00% | 33.33% | 33.33% | 100.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.85% | -22.75% | -37.05% | -53.22% | -47.25% |
| Operating Income | -17.40% | 24.30% | 37.40% | 53.22% | 47.25% |
| Income Before Tax | -17.60% | 21.97% | 30.74% | 48.85% | 43.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.60% | 21.97% | 30.74% | 48.85% | 43.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1,331.98% | -- | -- | -- | -- |
| Net Income | -6.61% | 30.12% | 40.08% | 54.31% | 43.65% |
| EBIT | -17.40% | 24.30% | 37.40% | 53.22% | 47.25% |
| EBITDA | -17.78% | 26.38% | 39.89% | 55.81% | 49.58% |
| EPS Basic | 32.78% | 68.83% | 68.96% | 75.92% | 70.53% |
| Normalized Basic EPS | 41.40% | 72.16% | 73.11% | 78.22% | 70.92% |
| EPS Diluted | 32.78% | 68.83% | 68.96% | 75.92% | 70.53% |
| Normalized Diluted EPS | 41.40% | 72.16% | 73.11% | 78.22% | 70.92% |
| Average Basic Shares Outstanding | -69.89% | 628.12% | 694.14% | 788.70% | 942.44% |
| Average Diluted Shares Outstanding | -69.89% | 628.12% | 694.14% | 788.70% | 942.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |